research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
Search
for
Sort by
Research
780-810 / 1000+ results
research Smoothened antagonists for hair inhibition
Two new compounds were found to effectively reduce hair growth in mice.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Hair loss and Hedgehog inhibitors: a class effect?
Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
research TREATMENT SUCCESS IN THREE ANDEAN BEARS (TREMARCTOS ORNATUS) WITH ALOPECIA SYNDROME USING OCLACITINIB MALEATE (APOQUEL®)
Oclacitinib maleate successfully treated alopecia in Andean bears.
research The efficacy of scalp-cooling system for the prevention of chemotherapy-induced hair loss in metastatic breast cancer patients treated with eribulin
A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.
research Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Sisaipho alopecia areata treated with tofacitinib and oral minoxidil
Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
research Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia
Suppressing eIF4E can prevent hair loss from chemotherapy.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research Bexxar, iodine I 131 tositumomab, Effective in Long Term Follow-up of Non-Hodgkin's Lymphoma
Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
research Beyond Hair Regrowth: Interpreting the Psychosocial Impact of Ritlecitinib in Alopecia Areata
Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
research Anticancer effects of metformin on neuroendocrine tumor cells in vitro
Metformin may help treat neuroendocrine tumors.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research Hedgehog Pathway Inhibitors against Tumor Microenvironment
Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.
research Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
research Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production
The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma
Pantethine may boost the immune system's ability to fight sarcoma.
research The Double-Edged Sword of Epidermal Growth Factor Receptor Inhibitor: Rash as Toxicity and Prognostic Marker
Rash from EGFRI treatment can indicate both side effects and treatment effectiveness.
research Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Golvatinib shows promise as a treatment for Omicron in elderly patients.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
research Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Dabrafenib can cause skin growths and sometimes low-grade skin cancer.